Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV
Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV
Simple item page
Full item details
- dc.contributor.author
- Chambers, Catharine
- Samji, Hasina
- Cooper, Curtis L.
- Costiniuk, Cecilia T.
- Janjua, Naveed Z.
- Kroch, Abigail E.
- Arbess, Gordon
- Benoit, Anita C.
- Buchan, Sarah A.
- Chung, Hannah
- Kendall, Claire E.
- Kwong, Jeffrey C.
- Langlois, Marc-André
- Lee, Samantha M.
- Mbuagbaw, Lawrence
- McCullagh, John
- Moineddin, Rahim
- Nambiar, Devan
- Walmsley, Sharon
- Anis, Aslam H.
- Burchell, Ann N.
- COVAXHIV Study Team
- dc.date.accessioned
- 2025-01-16T20:57:27Z
- dc.date.available
- 2025-01-16T20:57:27Z
- dc.date.issued
- 2022-12-01
- dc.description.abstract - en
- <p>Objective: People with HIV were underrepresented in coronavirus disease 2019 (COVID-19) vaccine clinical trials. We estimated vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for the BNT162b2, mRNA-1273, and ChAdOx1 vaccines among a population-based cohort of people with HIV in Ontario, Canada.</p> <p>Design: Test-negative design</p> <p>Methods: We identified people with HIV aged ≥19 years who were tested for SARS-CoV-2 by RT-PCR between December 14, 2020 (first availability of COVID-19 vaccines) and November 21, 2021 (pre-Omicron circulation). Outcomes included any infection, symptomatic infection, and COVID-19-related hospitalization/death. We compared the odds of vaccination between test-positive cases and test-negative controls using multivariable logistic regression with adjustment for age, sex, region, calendar time, SARS-CoV-2 test histories, influenza vaccination, comorbidities, and neighborhood-level socio-economic status. VE was derived as (1 – adjusted odds ratio) × 100%.</p> <p>Results: Among 21 023 adults living with HIV, there were 801 (8.3%) test-positive cases and 8,879 (91.7%) test-negative controls. 20.1% cases and 47.8% of controls received ≥1 COVID-19 vaccine dose; among two-dose recipients, 93.4% received ≥1 mRNA dose. Two-dose VE ≥7 days before specimen collection was 82% (95% confidence interval [CI] = 74–87%) against any infection, 94% (95% CI = 82–98%) against symptomatic infection, and 97% (95% CI = 85–100%) against hospitalization/death. Against any infection, VE declined from 86% (95% CI = 77–92%) within 7–59 days after the second dose to 66% (95% CI = −15–90%) after ≥180 days; we did not observe evidence of waning protection for other outcomes.</p> <p>Conclusion: Two doses of COVID-19 vaccine offered substantial protection against symptomatic illness and hospitalization/death in people with HIV prior to the emergence of the Omicron variant. Our findings do not support a broad conclusion that COVID-19 VE is lower among people with HIV in populations that, for the most part, are attending HIV care, taking antiretroviral medication, and are virally suppressed.</p>
- dc.identifier.doi
- https://doi.org/10.1097/qad.0000000000003405
- dc.identifier.issn
- 1473-5571
- dc.identifier.pubmedID
- 36254892
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/3326
- dc.language.iso
- en
- dc.publisher - en
- Wolters Kluwer Health, Inc.
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.subject.en - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject.fr - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.title - en
- Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV
- dc.type - en
- Article
- dc.type - fr
- Article
- local.article.journalissue
- 15
- local.article.journaltitle - en
- AIDS
- local.article.journalvolume
- 36
- local.pagination
- F17-F26
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
Download(s)
Original bundle
1 - 1 of 1
Name: chambers-coronavirus-disease-2019-vaccine-effectiveness-hiv.pdf
Size: 157.06 KB
Format: PDF
Collection(s)